West Pharmaceutical Services Inc. (WST) stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.
The company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.
West Pharma cited two key factors weighing on its guidance - biotech customers reducing inventory levels built up during pandemic-era supply chain disruptions, and headwinds from a strong U.S. dollar impacting overseas revenues. CEO Eric Green said the "impact of destocking continues to moderate" but is still an overhang.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。